Apply for Funding

CPRIT offers several funding opportunities for promising cancer research, product development, and prevention programs. All funding opportunities are announced through formal Requests for Applications (RFAs) and applications must be submitted through the online application receipt system.

Learn more about the grants process.

Individual Investigator Research Awards

Program Academic Research
RFA Status Open
Description

Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations.  Competitive renewal applications accepted.

Award: Up to $300,000 per year. Exceptions permitted if extremely well justified; maximum duration:  3 years.

Review Cycle Fiscal Year 2020 - Cycle 1
RFA Release January 10, 2019
Application Receipt March 07, 2019 - June 05, 2019
Application Review June 2019 - February 2020
Award Notification February 2020

Individual Investigator Research Awards for Cancer in Children and Adolescents

Program Academic Research
RFA Status Open
Description

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.

Award: Up to $300,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to $500,000 in total costs. Exceptions permitted if extremely well justified; maximum duration:  4 years.

Review Cycle Fiscal Year 2020 - Cycle 1
RFA Release January 10, 2019
Application Receipt March 07, 2019 - June 05, 2019
Application Review June 2019 - February 2020
Award Notification February 2020

Individual Investigator Research Awards for Clinical Translation

Program Academic Research
RFA Status Open
Description

Supports applications which propose innovative clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial or involve analyses of biospecimens from patients enrolled on a completed trial for which the outcomes are known. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices.

Award: Up to $400,000 per year. Maximum duration:  3 years. Applicants that plan on conducting a clinical trial as part of the project may request up to $600,000 in total costs and a maximum duration of 4 years. Exceptions permitted if extremely well justified.

Review Cycle Fiscal Year 2020 - Cycle 1
RFA Release January 10, 2019
Application Receipt March 07, 2019 - June 05, 2019
Application Review June 2019 - February 2020
Award Notification February 2020

Individual Investigator Research Awards for Prevention and Early Detection

Program Academic Research
RFA Status Open
Description

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, early-stage progression, and/or early detection of cancer. Research may be laboratory-, clinical-, or population- based, and may include behavioral/intervention, dissemination or health services/outcomes research to reduce cancer incidence or promote early detection. Competitive renewal applications accepted.

Award: Up to of $300,000 per year for laboratory and clinical research; Up to $500,000 per year for population-based research, including implementation research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Exceptions permitted if extremely well justified; maximum duration:  3 years.

Review Cycle Fiscal Year 2020 - Cycle 1
RFA Release January 10, 2019
Application Receipt March 07, 2019 - June 05, 2019
Application Review June 2019 - February 2020
Award Notification February 2020

Company Relocation Product Development Awards

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support early-stage “start-up” and established companies in the development of innovative products, services, and infrastructure with significant potential impact on patient care. The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust industry; or must fill a treatment or research gap. Companies must relocate to Texas upon receipt of award. Award: Maximum amount $20M; Maximum duration of 36 months.

Please note that in any given application round, applicants may apply for one Product Development award (TXCO, RELCO or Seed) at a time. Applicants are advised to review each RFA and select the program that best fits their development status. Please see the RFAs for additional instructions.

December 19, 2018 Webinar
Resources Available


View Webinars and Slides

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release December 05, 2018
Application Receipt December 05, 2018 - January 30, 2019
Application Review April 2019 - April 2019
Award Notification August 2019

Seed Awards for Product Development Research

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support projects that are too early in their development timeline to be eligible for CPRIT’s two other Product Development Awards, the Texas Company Award (TXCO) and the Company Relocation Award (RELCO). The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust industry; or must fill a treatment or research gap. Company applicants must be headquartered in Texas or be willing to relocate to Texas upon receipt of award.

Award: Maximum amount of $3M; Maximum duration of 36 months.

Please note that in any given application round, applicants may apply for one Product Development award (TXCO, RELCO or Seed) at a time. Applicants are advised to review each RFA and select the program that best fits their development status. Please see the RFAs for additional instructions.

September 19, 2018 SEED and December 19, 2018 Webinar
Resources Available


View Webinars and Slides

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release December 05, 2018
Application Receipt December 05, 2018 - January 30, 2019
Application Review April 2019 - April 2019
Award Notification August 2019

Texas Company Product Development Awards

Instructions for Applicants

Program Product Development Research
RFA Status Open
Description

This award mechanism seeks to support early-stage “start-up” and established companies in the development of innovative products, services, and infrastructure with significant potential impact on patient care. The proposed project must further the development of new products for the diagnosis, treatment, or prevention of cancer; must establish infrastructure that is critical to the development of a robust industry; or must fill a treatment or research gap. Companies must be headquartered in Texas.

Award: Maximum amount $20M; Maximum duration of 36 months.

Please note that in any given application round, applicants may apply for one Product Development award (TXCO, RELCO or Seed) at a time. Applicants are advised to review each RFA and select the program that best fits their development status. Please see the RFAs for additional instructions.

December 19, 2018 Webinar
Resources Available


View Webinars and Slides

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release December 05, 2018
Application Receipt December 05, 2018 - January 30, 2019
Application Review April 2019 - April 2019
Award Notification August 2019

Evidence-Based Cancer Prevention Services

Instructions for Applicants

Program Prevention
RFA Status Open
Description

Evidence-Based Cancer Prevention Services - This award mechanism seeks to fund projects that will deliver evidence-based cancer prevention and control clinical services. Priority will be given to projects that propose to address CPRIT areas of emphasis and serve areas of the state not well addressed by current CPRIT funded projects.

Award: Maximum of $1M; Maximum duration of 36 months.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release October 19, 2018
Application Receipt November 19, 2018 - February 20, 2019
Application Review May 2019 - July 2019
Award Notification August 2019

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to support the coordination and expansion of evidence based services to prevent cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence based models shown to work in similar communities to prevent and control these cancers. Currently funded CPRIT projects should propose to expand their programs to include additional types of prevention clinical services and/or an expansion of current clinical services into additional counties. In either case, the expansion must include delivery of services to nonmetropolitan and medically underserved counties in the state.

Award: Maximum of $2M; Maximum duration of 36 months.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release October 19, 2018
Application Receipt November 19, 2018 - February 20, 2019
Application Review May 2019 - July 2019
Award Notification August 2019

Tobacco Control and Lung Cancer Screening

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to fund programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT’s goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers. This RFA seeks to promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth.

Award: Maximum of $1M; Maximum duration of 36 months.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release October 19, 2018
Application Receipt November 19, 2018 - February 20, 2019
Application Review May 2019 - July 2019
Award Notification August 2019

Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center Award

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Supports a single Collaborative Action Center whose function will be to: (1) promote interactions and collaborations across the CAP Research Awards funded under the companion RFA, R-19.2 CAP:RA; (2) provide opportunities for academic content experts, health care providers and community stakeholders to exchange ideas and to explore new opportunities to impact the rise of hepatocellular cancer (HCC) in Texas and (3) educate health care providers and the public on best practices to alter the trajectory of HCC in Texas. Note applications for this award mechanism are subject to institutional limits. Applicants are advised to consult with their institutions’ Office of Research and Sponsored Programs (or equivalent).

Award: CPRIT plans to make one award. Up to $3,000,000 in total costs.

Maximum duration: 5 years.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release August 17, 2018
Application Receipt October 17, 2018 - January 30, 2019
Application Review February 2019 - August 2019
Award Notification August 2019

Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Investigator-Initiated Research Awards

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Supports investigator-initiated research projects designed to understand the reasons for the increased incidence of HCC in Texas, to identify risk factors for cirrhosis and HCC, to identify biomarkers for HCC early detection, and to develop and implement prevention and early detection strategies. CAP Research Awardees (under this RFA) must agree to participate in the Collaborative Action Center initiatives including the CAP Steering Committee’s meetings and initiatives and the CAP program outreach and educational mission

Award: CPRIT plans to make multiple awards in response to this RFA. Up to $500,000 in total costs per year.

Maximum duration: 5 years.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release August 17, 2018
Application Receipt October 17, 2018 - January 30, 2019
Application Review February 2019 - August 2019
Award Notification August 2019

Core Facility Support Awards (CFSA)

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer. CPRIT is particularly interested in supporting core facilities that provide enabling services to cancer investigators from multiple Texas institutions. Note applications for this award mechanism are subject to institutional limits. Applicants are advised to consult with their institutions’ Office of Research and Sponsored Programs (or equivalent).

Award: Up to $3 million (total costs) for the first 2 years and up to $1M (total costs) for each subsequent year.

Maximum duration: Five years.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release August 17, 2018
Application Receipt October 17, 2018 - January 30, 2019
Application Review February 2019 - August 2019
Award Notification August 2019

Early Translational Research Awards

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Supports projects that "bridge the gap" between promising new discoveries achieved in the research laboratory and commercial development for a therapeutic, device, or diagnostic assay through activities including preclinical proof-of-principle data that demonstrate applicability to the planned clinical scenario and preclinical toxicology and formulation to de-risk the development of lead compounds or devices. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. Presentation of a time line with stage gates for development is required. A public or private company is not eligible. Note applications for this award mechanism are subject to institutional limits. Applicants are advised to consult with their institutions’ Office of Research and Sponsored Programs (or equivalent).

Award: up to $ 2 million in total costs

Maximum duration: 1-2 years.

September 19, 2018 ETRA Webinar
Resources Available

View Webinar and Slides
View RFA FAQ

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release August 17, 2018
Application Receipt October 17, 2018 - January 30, 2019
Application Review February 2019 - August 2019
Award Notification August 2019

High-Impact/High-Risk Research Awards (HIHR)

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers. Note applications for this award mechanism are subject to institutional limits. Applicants are advised to consult with their institutions’ Office of Research and Sponsored Programs (or equivalent).

Award: Up to $200,000 (total costs)

Maximum duration: 2 years.

Review Cycle Fiscal Year 2019 - Cycle 2
RFA Release August 17, 2018
Application Receipt October 17, 2018 - January 30, 2019
Application Review February 2019 - August 2019
Award Notification August 2019

Recruitment of Established Investigators

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Award: Up to $6 million over a period of five years.

Review Cycle Fiscal Year 2019 - Cycle 1
RFA Release June 21, 2018
Application Receipt June 21, 2018 - June 20, 2019
Application Review Continuous
Award Notification Continuous

Recruitment of First-Time, Tenure-Track Faculty Members

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.

Award: Up to $2 million up to a period of five years.

Review Cycle Fiscal Year 2019 - Cycle 1
RFA Release June 21, 2018
Application Receipt June 21, 2018 - June 20, 2019
Application Review Continuous
Award Notification Continuous

Recruitment of Rising Stars

Instructions for Applicants

Program Academic Research
RFA Status Open
Description

Recruits outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Award: Up to $4 million over a period of five years.

Review Cycle Fiscal Year 2019 - Cycle 1
RFA Release June 21, 2018
Application Receipt June 21, 2018 - June 20, 2019
Application Review Continuous
Award Notification Continuous

Dissemination of CPRIT-Funded Cancer Control Interventions

Instructions for Applicants

Program Prevention
RFA Status Open
Description

This award mechanism seeks to fund projects that will facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas. The proposed project should be in a position to develop one or more “products” based on the results of the CPRIT-funded intervention. The proposed project should also identify and assist others to prepare to implement the intervention and/or prepare for grant funding.

Award: Maximum of $300,000; Maximum duration of 24 months

Review Cycle Fiscal Year 2019 - Cycle 1
RFA Release June 07, 2018
Application Receipt June 07, 2018 - June 04, 2019
Application Review Continuous
Award Notification Continuous
Apply Now Grants Process

Sign Up for Our Newsletter